CoChat

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are published. Patients received T-DXd 6.4 mg/kg every 3 weeks and were assigned to either: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+), cohort B (IHC 2+/ISH−), or cohort C (IHC 1+). Primary endpoint was objective response rate (ORR) by independent central review in cohort A. Secondary endpoints included ORR (cohorts B and C), duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and safety of T-DXd. 86 patients were enrolled (53 in cohort A, 15 in cohort B, and 18 in cohort C). Results of the primary analysis are published, reporting an ORR of 45.3% in cohort A. Here, we report the final results. No responses occurred in cohorts B or C. Median progression-free survival, overall survival, and duration of response were 6.9, 15.5, and 7.0 months, respectively. Overall serum exposure (cycle 1) of T-DXd, total anti-HER2 antibody, and DXd were similar regardless of HER2 status. Most common grade ≥3 treatment-emergent adverse events were decreased neutrophil count and anemia. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8 patients (9.3%). These findings support the continued exploration of T-DXd in HER2-positive mCRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-38032-4

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Antitumor activity of trastuzumab deruxtecan. A Waterfall plot showing the greatest percentage change from baseline in the sum of diameters of measurable tumors in patients with HER2-positive mCRC (cohort A). Each bar represents a patient. The line at 20% indicates progressive disease. The line at −30% indicates partial response. B Spider plot showing change over time from baseline in the sum of diameters of measurable tumors in cohorts A, B, and C. aFour patients from the full analysis set were excluded; 1 patient had no measurable target lesion and 3 patients had no postbaseline data. bBy local assessment. cOne patient from cohort B and 5 patients from cohort C had missing postbaseline data. HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, ISH in situ hybridization.
Fig. 1 Antitumor activity of trastuzumab deruxtecan. A Waterfall plot showing the greatest percentage change from baseline in the sum of diameters of measurable tumors in patients with HER2-positive mCRC (cohort A). Each bar represents a patient. The line at 20% indicates progressive disease. The line at −30% indicates partial response. B Spider plot showing change over time from baseline in the sum of diameters of measurable tumors in cohorts A, B, and C. aFour patients from the full analysis set were excluded; 1 patient had no measurable target lesion and 3 patients had no postbaseline data. bBy local assessment. cOne patient from cohort B and 5 patients from cohort C had missing postbaseline data. HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, ISH in situ hybridization.CC BY · PubMed Central
Fig. 2 Progression-free survival and overall survival in patients with HER2-positive and HER2-low mCRC receiving trastuzumab deruxtecan. Kaplan–Meier curves representing (A) progression-free survival and (B) overall survival. Marks indicate where data were censored. HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, ISH in situ hybridization, NE not evaluable.
Fig. 2 Progression-free survival and overall survival in patients with HER2-positive and HER2-low mCRC receiving trastuzumab deruxtecan. Kaplan–Meier curves representing (A) progression-free survival and (B) overall survival. Marks indicate where data were censored. HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, ISH in situ hybridization, NE not evaluable.CC BY · PubMed Central
Fig. 3 Objective response rate and progression-free survival by patient subgroups in patients with HER2-positive (cohort A) mCRC receiving trastuzumab deruxtecan. A, B Forest plot of subgroups for (A) objective response ratea. Data are presented as the point estimate of ORR with its exact 95% CI. The dotted line represents the ORR of patients in the HER2 + cohort A (45.3%). Forest plot of subgroups for (B) progression-free survival. Data are presented as median PFS with its exact 95% CI. The dotted line represents the median PFS of patients in the HER2 + cohort A (6.9 months). aReprinted from ref. 16, with permission from Elsevier. bLeft: rectum, sigmoidal, descending; right: cecum, ascending, transverse. ECOG PS Eastern Cooperative Oncology Group performance status, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, ISH in situ hybridization, mCRC metastatic colorectal cancer.
Fig. 3 Objective response rate and progression-free survival by patient subgroups in patients with HER2-positive (cohort A) mCRC receiving trastuzumab deruxtecan. A, B Forest plot of subgroups for (A) objective response ratea. Data are presented as the point estimate of ORR with its exact 95% CI. The dotted line represents the ORR of patients in the HER2 + cohort A (45.3%). Forest plot of subgroups for (B) progression-free survival. Data are presented as median PFS with its exact 95% CI. The dotted line represents the median PFS of patients in the HER2 + cohort A (6.9 months). aReprinted from ref. 16, with permission from Elsevier. bLeft: rectum, sigmoidal, descending; right: cecum, ascending, transverse. ECOG PS Eastern Cooperative Oncology Group performance status, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, ISH in situ hybridization, mCRC metastatic colorectal cancer.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 188

Metadata

Authors
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., Rodriguez, J., Fakih, M., Ciardiello, F., Saxena, K., Kobayashi, K., Bako, E., Okuda, Y., Meinhardt, G., Grothey, A., Siena, S., DESTINY-CRC01 investigators, & Di Bartolomeo, M.
Affiliations
  • National Cancer Center Hospital East (JP)
  • The University of Texas MD Anderson Cancer Center (US)
  • Aichi Cancer Center Hospital (JP)
  • Istituto Oncologico Veneto (IT)
  • Kindai University Hospital (JP)
  • The Cancer Institute Hospital (JP)
  • Shikoku Cancer Center (JP)
  • Ronald Reagan UCLA Medical Center (US)
  • Clinica Universidad de Navarra (ES)
  • City Of Hope National Medical Center (US)
  • University of Campania "Luigi Vanvitelli" (IT)
  • Daiichi Sankyo (United States) (US)
  • Daiichi-Sankyo (Japan) (JP)
  • West Cancer Center (US)
  • University of Milan (IT)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Corresponding author
Siena, Salvatore
Venue
Nature Communications
Published
2023-06-07
Volume
14
Issue
1
Pages
3332-3332
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4379740210
Cited by
178
References
50
Citations by year
2026: 48 · 2025: 62 · 2024: 58 · 2023: 10
FWCI
21.71
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Funders
Daiichi Sankyo and AstraZeneca
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
trastuzumab deruxtecan, antibody-drug conjugates, objective response rate, progression-free survival, overall survival, interstitial lung disease, neutropenia, anemia, HER2 immunohistochemistry, in situ hybridization, treatment-emergent adverse events
MeSH terms
Trastuzumab, Breast Neoplasms, Camptothecin, Colonic Neoplasms, Female, Humans, Rectal Neoplasms, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. https://app.cochat.ai/papers/10.1038/s41467-023-38032-4
The paper
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., Rodriguez, J., Fakih, M., Ciardiello, F., Saxena, K., Kobayashi, K., Bako, E., Okuda, Y., Meinhardt, G., Grothey, A., . . . Di Bartolomeo, M. (2023). Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nature Communications. https://doi.org/10.1038/s41467-023-38032-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.